image credit: Pixabay

FDA approves Medtronic’s insulin delivery and monitoring system

September 1, 2020


The US Food and Drug Administration (FDA) has approved Medtronic’s MiniMed 770G System for use by paediatric patients aged between two and six years with type 1 diabetes.

The system is a hybrid closed-loop diabetes management device, which automatically monitors glucose and enables appropriate basal insulin doses with little or no input from the users or their caregivers.

It is designed to measure the glucose levels in the body every five minutes and automatically adjust insulin delivery by either administering or withholding insulin.

It is a Bluetooth-enabled version of the company’s previously approved MiniMed 670G System.